

3 January 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

ReNeuron Group plc
("ReNeuron" or the "Company")

Directorate Change
Iain Ross appointed as Executive Chairman, CEO steps down

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell-derived exosome technologies, announces that Catherine Isted, ACMA, Chief Executive Officer ("CEO") has stepped down from her role with immediate effect.

Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course.

On behalf of the ReNeuron Board of Directors, Barbara Staehelin, Senior Independent Director, commented: *"We would like to thank Catherine for her contribution over the past 17 months, initially as CFO and more recently as CEO, and wish her well in the future. We are excited about the future of the Company and are very grateful to Iain for agreeing to lead the Company going forward. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc."*

ENDS

Contacts:

ReNeuron

Iain Ross, Executive Chairman
John Hawkins, Chief Financial Officer

www.reneuron.com/investors

Via Walbrook PR

Liberum Capital Limited (NOMAD and Joint Broker)

Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking)

+44 (0)20 3110 2000

Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus / Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding

area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com